Navigation Links
American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI
Date:11/15/2009

Study highlights:

- A new reversible, intravenous blood thinner did not show superiority over an irreversible one currently approved for use.

- Further investigation of the new anti-clotting drug is warranted.

ORLANDO, Fla., Nov. 15 /PRNewswire-USNewswire/ -- A new, reversible antiplatelet drug did not demonstrate superiority over a current irreversible one in reducing the composite of death, heart attack or ischemia-related revascularization in the 48 hours after angioplasty, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

The primary endpoint for CHAMPION PCI was not met, but study researchers say they did find some potential benefit of the new drug, cangrelor, that warrants further investigation.

"Our findings combined with those from a companion trial (CHAMPION PLATFORM) suggest that cangrelor reduces the risk of some clinically meaningful ischemic events in patients undergoing percutaneous coronary intervention (PCI)," said Robert A. Harrington, M.D., principal investigator of the study and professor of medicine at Duke University and director of the Duke Clinical Research Institute in Durham NC. "That includes a possible reduction in Q wave infarction and stent thrombosis."

In CHAMPION PCI -- a phase III, multi-national (200 sites, 18 countries), randomized, double-blind, placebo-controlled trial-- researchers tested the hypothesis that cangrelor provides superior or at least non-inferior performance compared to a 600 milligram (mg) dose of clopidogrel during the 48 hours after PCI.

Investigators planned to enroll about 9,000 patients, but the trial was stopped early (May 2009) with 8,820 patients enrolled after an interim review panel concluded it was unlikely to meet its primary endpoint.

Patients were randomly assigned to receive cangrelor or clopidogrel, the FDA-a
'/>"/>

SOURCE American Heart Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Viron to Present Data from Phase II Trial at American Heart Association Conference
2. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
3. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
4. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
5. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
6. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
7. American Oriental Bioengineering Announces September Investor Conferences Participation
8. American Scientific Resources To Be Exclusive Seller of Worlds Only FDA Approved Home Needle Destruction Device
9. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
10. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
11. American Oriental Bioengineering Announces Change in Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... studies characterizing the analgesic profiles of a series ... receptor agonist molecules. The preclinical research candidates were ... platform. The analgesic properties of kappa ... literature. 1,2 Kappa opioid receptors are expressed ...
(Date:9/19/2014)... September 19, 2014 Barnhardt Manufacturing ... Label for its Organic Cotton . The USDA ... of renewable biobased ingredients meets or exceeds levels set ... composed in whole or in significant part of agricultural, ... allow our Organic cotton to be immediately identified as ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... REDWOOD CITY, Calif., Aug. 5 Ingenuity ... life science researchers,today introduced Ingenuity Analysis Services, ... ,omics data related to,compound profiling, target identification, ... are designed to meet the needs of ...
... second quarter stock repurchase program and positive cash flow from ... ... (Nasdaq: AMCS ), a,leader in radiology and medical image and information ... 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ), Q2 ...
... Quarterly Dacogen Royalty Revenue Increases 76% from Same ... SuperGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... months ended June 30, 2008., Total revenues ...
Cached Biology Technology:Ingenuity Systems Launches Analysis Services 2AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 2AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 3AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 4AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 5AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 6AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 7AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 8AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 9AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 10AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 11AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 12SuperGen Reports 2008 Second Quarter Financial Results 2SuperGen Reports 2008 Second Quarter Financial Results 3SuperGen Reports 2008 Second Quarter Financial Results 4SuperGen Reports 2008 Second Quarter Financial Results 5SuperGen Reports 2008 Second Quarter Financial Results 6SuperGen Reports 2008 Second Quarter Financial Results 7SuperGen Reports 2008 Second Quarter Financial Results 8SuperGen Reports 2008 Second Quarter Financial Results 9SuperGen Reports 2008 Second Quarter Financial Results 10SuperGen Reports 2008 Second Quarter Financial Results 11SuperGen Reports 2008 Second Quarter Financial Results 12SuperGen Reports 2008 Second Quarter Financial Results 13
(Date:9/19/2014)... Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ... growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ad ... light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... Katey Sagal have been cast in Bleed for ...
(Date:9/18/2014)... A new GSA Bulletin study uses tree ... Puerco and Chaco Wash in northern New Mexico, USA. ... cedar and willow, investigators were able to precisely date ... then combined this data with aerial imagery, LiDAR, longitudinal ... these arroyos. , Arroyos are deep, oversized channels that ...
(Date:9/18/2014)... SAN ANTONIO, September 18, 2014 New research into ... which causes a severe hemorrhagic disease in humans similar ... factors essential for CCHFV infection. This discovery has the ... against the pathogen. , The research, reported ... PLoS Pathogens and conducted by scientists at the ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Research milestone in CCHF virus could help identify new treatments 2
... over face threats on many fronts: pollution, diseases, destructive fishing ... resistant to one potential menace seaweed than previously ... scientists from the United States and Australia. Their study ... individual reefs in all, more than 3,500 examinations of ...
... different species are likely to respond to climate change. ... species and the interactions between species, in the interest ... BioScience , by Eric Post of Pennsylvania State ... be avoided. Their approach, which relies on multi-stage analyses ...
... (June 1, 2009) The International Serious Adverse Events ... designed to discover genetic markers that may predict individuals ... The SAEC is a nonprofit research corporation, launched ... by 10 leading pharmaceutical companies and the Wellcome Trust. ...
Cached Biology News:In the turf war against seaweed, coral reefs more resilient than expected 2International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury 2International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury 3
... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
... thermostable DNA polymerase obtained by high level ... in E. coli, Concentration: 5U/ul, Applications: Standard ... Scientific, the world leader in serving science. ... the world healthier, cleaner and safer by ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Biology Products: